Certara Launches Version 8.3 of Phoenix™ Biosimulation Software for Drug Development
Latest updates demonstrate commitment to customers and market leadership of Phoenix Platform
Explore Our Scientific Resource Library
Certara Broadens and Increases Regulatory Strength with Two Executive Hires
PRINCETON, N.J.—May 21, 2020 — New executives bring strategic and cross-disciplinary expertise to navigate changing regulatory environments
Certara & DMTC Collaborate to Study Using Chloroquine in Healthcare Workers at Risk for COVID-19
Certara applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19
Certara Launches New Version of Simcyp® Simulator for Population-Based Pharmacokinetic Modeling and Simulation
Version 19 offers mechanistic models for assessing maternal-fetal drug risk, developing drug formulations, and optimizing dermal and transdermal drug development
Certara Launches COVID-19 Pharmacology Online Resource Center
Funded by the Bill & Melinda Gates Foundation, the online Center helps accelerate therapeutics for COVID-19 by integrating clinical pharmacology, innovation and collaboration
Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc.
PRINCETON, NJ – Feb. 25, 2020 – Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc. Acquisition will spur the development of new drugs to treat complex neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease.
Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research
PRINCETON, NJ – Feb. 10, 2020 – Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research
Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Sixth Consecutive Year
PRINCETON, NJ – Jan. 23, 2020 – Certara today reported that more than 90% of novel new drug approvals by the US Food and Drug Administration (FDA) in 2019 were supported by Certara software or services.
Certara Partners with Galderma to Attain FDA Approval of AKLIEF® Topical Acne Cream
PRINCETON, NJ – Jan. 8, 2020 – Certara’s Simcyp® Simulator’s MechDermA™ model provided safety label claim and pediatric dosing information without the need for testing in clinical patients for a topical drug product.
LEO Pharma Joins Certara’s PBPK Simcyp Simulator Consortium
PRINCETON, NJ – Dec. 10, 2019 – LEO Pharma has licensed Certara’s proprietary Simcyp®️ Population-based Simulator and joined its Consortium.
Solution:
PBPK Modeling & Simulation
